skip to main |
skip to sidebar
April 23, 2008--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) today announced an extension to the sponsored research term under its collaboration with Merck & Co., Inc. for an additional year, through June 2009.
The two companies will continue their joint efforts to identify novel small molecule therapeutics with the potential to treat several diseases, including type 2 diabetes and other metabolic diseases, by activation of an enzyme called AMP-activated Protein Kinase (AMPK). AMPK is thought to play an important role in regulating carbohydrate and fat metabolism and consequently in metabolic diseases such as type 2 diabetes... Metabasis' Press Release -
Feb. 28, 2008--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced the completion of patient enrollment in its Phase 2a clinical trial for MB07803, a product candidate being studied as a treatment for patients with type 2 diabetes. With this trial fully enrolled and the final patients undergoing dosing, the Company expects to be able to announce top line results in the second quarter of 2008, as planned. MB07803 is a member of a new class of drugs discovered by Metabasis that is designed to regulate glucose production in the liver by inhibiting an enzyme known as fructose-1,6-bisphosphatase (FBPase), a key enzyme in the gluconeogenesis pathway which is responsible for the excessive production of glucose in patients with type 2 diabetes... Metabasis Therapeutics' Press Release -
Sept. 17, 2007--Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced that a poster entitled "A Novel Glucagon Antagonist Inhibits Glucagon-Stimulated Glucose Production in Human Hepatocytes and Lowers Blood Glucose in Animal Models of Type 2 Diabetes" was presented during the 43rd Annual Meeting of the European Association for the Study of Diabetes (Amsterdam, The Netherlands). The poster provides data from several preclinical studies that show a class of small molecule glucagon antagonists discovered by Metabasis has demonstrated promising glucose lowering activity in various animal models of type 2 diabetes... Metabasis Therapeutics' Press Release -
